Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab

Howard M. Stern1, Mary Padilla4, Klaus Wagner2,5, Lukas Amler2, and Avi Ashkenazi3

Abstract

**Purpose:** In vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist antibody) is strongly predicted by the expression of the O-glycosylation enzymes GALNT14 in non–small cell lung cancer (NSCLC) cell lines (among others) and of FUT3/6 in colorectal cancer (CRC) cell lines. We developed immunohistochemistry (IHC) assays that measure GALNT14 and FUT3/6 levels in archival formalin-fixed, paraffin-embedded human tumor tissue to determine marker prevalence in NSCLC and CRC tissue and to enable the future examination of these markers in clinical trials.

**Experimental Design:** GALNT14 or FUT3/6 ELISA-positive hybridoma clones were screened through IHC on cell pellets with known mRNA levels. The specificity of staining was examined in cell lines, normal tissue, and tumor tissue.

**Results:** GALNT14 and FUT3/6 IHC exhibited a golgi staining pattern and correlated with GALNT14 and FUT3/6 (but not GALNT2 and FUT4) mRNA expression levels in cell lines and normal tissues, suggesting specificity. GALNT14 and FUT3/6 H-scores were significantly higher in cell lines sensitive to dulanermin (P = 0.01 and P = 0.0004, respectively) and drozitumab (P = 0.03 and P < 0.0001, respectively) versus resistant cell lines. GALNT14 and FUT3/6 H-scores varied widely, with ~45% of NSCLC samples exhibiting weak to moderate GALNT14 staining (H-score of at least 25) and 70% of CRC samples exhibiting moderate to strong FUT3/6 staining (H-score of at least 125).

**Conclusions:** GALNT14 and FUT3/6 expression can be assessed in human tumors using sensitive and specific IHC assays. Both assays are being deployed in ongoing clinical trials of dulanermin and drozitumab to assess potential utility for patient selection.

**Developing oncology drugs that have significant effect for patients has proven to be challenging for many reasons. One contributing factor is the diversity, at the molecular level, of tumors that are classified similarly on the basis of histology. As a consequence, most oncology chemotherapeutics do not impart a clinically meaningful benefit in all treated patients. One strategy for addressing this deficit is the identification of molecular correlates of response (or resistance) to specific therapies to better match drugs with patients who have a high probability of clinical benefit. Accomplishing this task during drug development involves early efforts to identify potential biomarkers in preclinical models and the development of appropriately validated diagnostic assays that can test these biomarkers in early-stage clinical trials.**

Agents that target apoptosis are currently the subject of intense investigation and stand to benefit from the development of diagnostic biomarkers. Most cells with cancer-initiating potential are eliminated from the body by apoptosis, but some cells harbor mutations that enable them to escape apoptosis, resulting in cell survival and the development of malignant tumors (2, 3). As our understanding of the molecular basis of apoptosis has increased, so too has research in the development of proapoptotic agents that tip the balance toward tumor cell death. The complex signaling cascade that leads to apoptosis is initiated either intracellularly through the intrinsic pathway or as a result of extracellular signals that trigger the extrinsic pathway (2, 3). Manipulation of the extrinsic pathway has been a major focus of drug discovery. Stimulation of this pathway begins with the binding of a proapoptotic ligand such as apoptosis ligand 2/tumor necrosis factor–related

**Authors' Affiliations:** Departments of 1Research Pathology, 2Development Oncology Diagnostics, and 3Molecular Oncology, Genentech, Inc., South San Francisco, California; 4Ventana Medical Systems, Inc., Tucson, Arizona; and 5M.D. Anderson Cancer Center, Houston, Texas

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

**Corresponding Authors:** Howard M. Stern, Department of Research Pathology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-467-3184; Fax: 650-225-8193; E-mail: hstern@gene.com and Avi Ashkenazi, Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-1853; Fax: 650-467-8193; E-mail: aash@gene.com.

**doi:** 10.1158/1078-0432.CCR-09-3108

©2010 American Association for Cancer Research.
certain cell lines and correlated with dulanermin sensitivity in pancreatic cancer. The expression of GALNT14 and FUT3/6 in cell lines from several tumor types. Furthermore, in colo-leukemia cell lines, with up to 30% of tissue samples from a variety of human cancers having relative GALNT14 mRNA expression at levels comparable with those seen in dulanermin-sensitive cell lines (1). In CRC cell lines, GALNT3 rather than GALNT14 mRNA levels were correlated with sensitivity (P = 0.026), as were levels of FUT3 and FUT6 mRNA. In fact, high FUT3 and FUT6 levels were better predictors of sensitivity than was GALNT3 (P = 0.01 for FUT3 and P = 0.0013 for FUT6). Notably, FUT3 and FUT6 mRNA expression levels were highly correlated with each other in these cell lines, suggesting that regulation of expression of these genes is coordinated. Overall, the high expression of GALNT14, GALNT3, FUT3, and FUT6 could predict responsiveness to dulanermin in 61% of cell lines (positive predictive value) and a lack of sensitivity in 88% of cell lines (negative predictive value; ref. 1).

Wagner et al. (1) also showed a functional link between death receptor O-glycosylation and apoptotic signaling. Both pharmacologic inhibition of glycosylation and enzyme knockdown through small interfering RNAs targeting GALNT14-, GALNT3-, and FUT6 reduced dulanermin-induced apoptosis. Furthermore, GALNT14 overexpression in pancreatic cancer cells substantially increased death-inducing signaling complex formation and caspase-8 and caspase-3 processing, whereas the progressive mutation of DR5 at sites of O-glycosylation weakened apoptotic signaling. In addition, GALNT14 knockdown in pancreatic cancer cells and FUT6 knockdown in colon cancer cells reduced caspase-8 processing, but did not appreciably alter DR4 or DR5 levels (1), supporting the conclusion that the glycosylation status of DR4/5 can affect apoptotic signaling independent of DR4/5 levels. Biochemical analysis further revealed that O-glycosylation facilitates ligand-induced clustering of DR4 and DR5, an event required for the efficient recruitment and activation of caspase-8 (1).

More recently, this body of work has been expanded to the examination of sensitivity to the DR5-agonist antibody, drozitumab. As observed for dulanermin, drozitumab sensitivity correlates with the expression of GALNT3, GALNT14, and FUT3/6 expression in several tumor cell types (19). In pancreatic cancer and NSCLC cell lines, statistically significant correlations were observed between GALNT14 levels and drozitumab sensitivity (P = 0.00029), whereas in CRC, GALNT3 and FUT3/6 levels were correlated with drozitumab sensitivity, with FUT6 being most strongly predictive (P = 0.00013; ref. 19).

Taken together, the results of the Wagner and Punnoose studies indicate, among other things, that GALNT14 levels may be a predictive biomarker for dulanermin- and drozitumab-based therapy in NSCLC (among other indications), whereas FUT3/6 may be a predictive biomarker in CRC. To further test these findings in clinical trials, we developed immunohistochemistry (IHC) assays to measure protein levels of these enzymes in formalin-fixed, paraffin-embedded (FFPE) cancer tissues. The results of the assay validation are presented in this report, as

Translational Relevance

The use of predictive diagnostic biomarkers to identify patients who may best respond to a particular type of cancer treatment is emerging as a crucial paradigm in the development of novel cancer therapies. Previous work (1) reported the identification of the O-glycosylation enzymes GALNT14 and FUT3/6 as potential diagnostic biomarkers for predicting response to proapoptotic death receptor agonists. We have developed and validated immunohistochemistry assays to detect GALNT14 and FUT3/6 in human tissue and describe the prevalence of expression in non–small cell lung cancer and colorectal cancer. These assays will enable the examination of GALNT14 and FUT3/6 in clinical trials of proapoptotic death receptor agonists.
well as the findings on the distribution of GALNT14 and FUT3/6 in NSCLC and CRC tumors.

Materials and Methods

Antigen and antibody production and screening. cDNAs coding for amino acids 40 to 552 of GALNT14 and 46 to 359 of FUT6 were cloned into a pRK expression vector with the addition of an NH$_2$-terminal His tag for GALNT14 and an NH$_2$-terminal Flag tag for FUT6. The vectors were subsequently transfected into Chinese hamster ovary cells for protein production, and the tagged proteins were purified by affinity chromatography using nickel or anti-Flag antibody columns.

Recombinant His-tagged GALNT14 and Flag-tagged FUT6 were denatured in a 0.5% SDS solution at 80°C for 20 min. Female BALB/c mice were hyperimmunized, through the footpad, twice weekly for a total of 12 to 13 boosts with 2 μg/animal denatured antigen resuspended in monophosphoryl lipid A/trehalose dicorynomycolate–based adjuvant (Corixa Corp.). Three days after the final boost, popliteal lymph node cells were extracted and fused with cells derived from the murine myeloma cell line P3X63Ag1.1 (ATCC CRL1597; American Type Culture Collection) using 50% polyethylene glycol or electroporation (CytoPulse Sciences, Inc.). Hybridoma cells were selected using hypoxanthine-aminopterin-thymidine–based media (ClonaCell Medium D, StemCell Technologies). Ten to 14 d postfusion, culture supernatants were collected and screened by direct ELISA for specific binding to denatured His-GALNT14 or Flag-FUT6 versus a SDS-denatured His-tagged or Flag-tagged control protein. For FUT6, an additional ELISA screen determined specific binding to denatured Flag-FUT3.

After the initial screen by ELISA, supernatants were screened through IHC on a tissue microarray constructed from FFPE cell pellets that were known to have high or low mRNA expression of the antigens. IHC-positive cell lines were subcloned two to four times by limiting dilution, and those showing strongest reactivity by ELISA and IHC were scaled up in CellLine Bioreactor Flasks (CL1000, Argos Technologies) for the in vitro production of monoclonal antibodies. Bioreactor-generated supernatant was purified by Protein A affinity chromatography, and purified antibody preparations were sterile filtered (0.2-mm pore size; Nalgene) and stored at 4°C in PBS.

IHC protocols. Prototype IHC assay protocols for GALNT14 and FUT3/6 were developed on the BenchMark XT automated staining platform (Ventana Medical Systems, Inc.) using ultraView Universal HRP Multimer (Ventana Medical Systems, Inc.) as the secondary antibody, ultraView Universal DAB (Ventana Medical Systems, Inc.) for the detection system, and Hematoxylin II (Ventana Medical Systems, Inc.) for the counter stain.

The antigen retrieval conditions were tested as follows: no pretreatment, mild Cell Conditioning 1 (Ventana Medical Systems, Inc.; 30 min, 100°C; pH 8), standard Cell Conditioning 1 (60 min, 100°C; pH 8), and mild Cell Conditioning 2 (30 min, 100°C; pH 6) using FFPE normal kidney tissue for GALNT14 and normal colon for FUT3/6. In both cases, standard Cell Conditioning 1 achieved the best staining characteristics, with a primary antibody incubation time of 16 min and temperature of 37°C. For GALNT14, two clones (5C4 and 3F11) were titered on FFPE normal kidney tissue, NSCLC tissues, and NSCLC cell pellets. 3F11 was the more sensitive antibody and was chosen for the final assay with a dilution of 1.6 μg/mL. For FUT3/6, the 1G11 clone was titered on FFPE normal colon, CRC, and CRC cell pellets, and a 1.3 μg/mL dilution chosen. The final dilution for both assays maximized signal-to-noise ratio across the tissues and cell lines tested. Five primary antibody diluents were tested, and Ventana Tris-HCl primary antibody diluent (Ventana Medical Systems, Inc.) was found to be optimal.

ELISA screening. To screen hybridoma cell supernatant, ELISA was done as previously described (32). Briefly, 96- or 384-well plates were coated with 50 to 100 μL of denatured, tagged antigen or denatured, tagged control protein at 1 μg/mL in coating buffer [0.05 mol/L carbonate buffer (pH 9.6)], sealed, and stored overnight at 4°C. After removing the coating solution, 200 μL (100 μL for a 384-well plate) of assay/blocking solution containing 0.5% bovine serum albumin and 0.05% Tween 20 in PBS (pH 7.4; ELISA diluent) was added to each well, and plates were incubated at room temperature for 1 h with agitation. Wells were then washed thrice with 300 μL (or 120 μL for a 384-well plate) 0.05% Tween 20 in PBS (wash buffer).

After the washing step, 100 μL (50 μL for a 384-well plate) of supernatant from each individual hybridoma clone was added to each well containing denatured, tagged antigen or denatured, tagged control protein. Plates were incubated at room temperature for 1 h with agitation, and the wells were washed thrice with wash buffer as before. After washing, 100 μL (50 μL for a 384-well plate) of a 1:1,000 dilution of peroxidase-conjugated goat IgG fraction to mouse IgG Fc (MP Biomedicals) in ELISA diluent was added to each well. Plates were incubated at room temperature for 1 h with agitation, washed thrice with wash buffer as before, and patted dry. Wells were developed by adding 100 μL (50 μL for a 384-well plate) of the tetramethylbenzidine microwell peroxidase substrate (BioFX Laboratories) to each well and incubating at room temperature for 5 to 10 min or until a good color change was observed. Development was stopped by adding 100 μL (50 μL for a 384-well plate) of the tetramethylbenzidine Stop Solution (BioFX Laboratories) to each well. Plates were analyzed with a Sunrise plate reader (Tecan US, Inc.) at 650 nm. Prebleed and polysera were used as controls. Prebleed samples contained mouse sera before immunization, and polysera samples contained mouse anti-sera obtained after 7 to 10 immunizations.

Cell lines. Panels of NSCLC and CRC cell lines were obtained from the American Type Culture Collection (authenticates through genomic and phenotypic approaches) or the German Collection of Microorganisms and Cell Cultures (authenticates through DNA typing,
cytogenetic and immunophenotypic tests) and passaged for <6 mo after resuscitation. Cell lines were treated with dulanermin or drozitumab to determine responsiveness as previously described (1, 19). The same cell lines were subjected to Affymetrix (Affymetrix, Inc.) mRNA expression profiling (1) and were processed into FFPE cell pellets for IHC. The following NSCLC cell lines were used in this study: A427, A549, CALU-1, EKVX, H1129, H1435, H1568, H1650, H1666, H1703, H1793, H1838, H1975, H2009, H2030, H2122, H2126, H226, H23, H2405, H292, H322T, H358, H441, H460, H520, H522, H596, H647, H650, H661, HOP-18, HOP-62, HOP92, LXF8-529, NCI-1781, NCI-H1155, NCI-H1651, NCI-H838, SK-MES, and SW1857. The following CRC cell lines were used in this study: C170, CACO-2, CL11, CL-34, COLO 205, Colo205, Colo206-F, Colo320 HSR, Colo320-DM, Colo678, Colo741, CX-1, DLD-1, HCT 8, HCT-116, HCT15, HT29, HT55, KM12, LoVo, Si1034, Si180, RKO-A545.1, RKO, SK-CO-1, SW 1417, SW116, SW403, SW480, SW620, SW837, and SW498. The mRNA expression of the various GALNT and FUT family genes was determined from previously described data sets available through GeneLogic (normal tissues) or through Affymetrix-based gene profiling (cell lines; ref. 1). The Affymetrix gene probes (Affymetrix, Inc.) used were as follows: GALNT4-219271_at, GALNT2-217788_s_at, FUT5-211225_at, FUT6-211465_x_at, FUT2-219271_at, FUT6-211465_x_at, FUT4-211145_x_at, FUT5-211225_at, and FUT7-210506_at.

FFPE cell pellets were produced by growing eight T175 flasks for each cell line, dislodging cells with 10 mmol/L EDTA (pH 8.0) followed by centrifugation, washing in PBS, and then fixation overnight in 10% neutral buffered formalin. Fixed pellets were processed in a Tissue-Tek processor (Sakura Finetek USA) and then embedded in a paraffin block.

Tissues. Normal tissues (including, lung, kidney, colon, and prostate) and cancer tissues (including CRC and NSCLC) were obtained from commercial vendors, without any personal identifiers and without any clinical outcome information. Tissue microarrays were created from cell pellet blocks or tissue blocks with a tissue arrayer (Beecher Instruments) using duplicate or triplicate 0.6-mm cores.

Scoring of IHC staining. For GALNT14 and FUT3/6, data from cell lines and tissues were collected as H-score components based on the H-score approach initiated by McCarty and colleagues (20). The percentage of tumor cells with no staining (0), weak staining (1+), moderate staining (2+), and strong staining (3+) was recorded for each sample. This information was summarized into a single H-score that was the sum of the percent with a score of 1+, twice the percent 2+, and thrice the percent 3+.

Results

GALNT14 IHC assay validation in NSCLC. Mouse monoclonal antibodies to GALNT14 were produced by immunizing mice with GALNT14 protein (amino acids percent 3+).

Fig. 1. Examples of GALNT14 IHC. Immunohistochemical staining patterns in cell lines and normal tissues known to express this enzyme (B and D) and known to lack this enzyme (A and C). A, H1435 NSCLC cell line; B, HOP18 NSCLC cell line; C, normal lung tissue; D, normal renal tubes. Scale bar, 50 μm.
a correlation coefficient of 0.70 (Fig. 2A). There was no evidence of correlation between GALNT14 IHC H-score and mRNA expression of the most closely related GALNT family member, GALNT2 (Fig. 2B), which is 50% identical and 67% similar to GALNT14 at the amino acid level (22), suggesting specificity for GALNT14.

The same cell lines had been previously grouped into those that are highly sensitive, moderately sensitive, or resistant to dulanermin and drozitumab (1, 19). GALNT14 IHC H-scores were significantly higher in the highly sensitive cell lines than in resistant cell lines for both dulanermin \( (P = 0.01) \) and drozitumab \( (P = 0.03; \text{Fig. 2C and D}) \).

As a next step in evaluating specificity, we used a database of the Affymetrix gene expression profiling on normal human tissues (GeneLogic) to identify tissues that were relatively high or low in expression of GALNT14 and its most closely related family member, GALNT2. GALNT14 expression is high in normal kidney tissue and low in normal lung tissue (Supplementary Fig. S1). By GALNT14 IHC, punctate perinuclear staining was observed in renal tubules, and no expression was observed in normal lung tissue (Fig. 1C and D), consistent with mRNA expression. By contrast, GALNT2 mRNA expression is equivalent and relatively low in kidney and lung tissue (Supplementary Fig. S1). Together, these data support the conclusion that the GALNT14 IHC assay exhibits evidence of specificity.

The GALNT14 IHC protocol validated on cell lines and normal tissue was then applied to a tissue microarray representing 67 archival NSCLC specimens. Again, the percentage of tumor cells with no staining (0), weak staining intensity (1+), moderate staining intensity (2+), and strong staining intensity (3+) was recorded and then

---

**Fig. 2.** GALNT14 assay validation. Correlation of GALNT14 IHC H-scores with (A) GALNT14 mRNA levels \( (r^2 = 0.70) \) and (B) GALNT2 mRNA levels \( (r^2 = 0.00003) \) in 41 NSCLC cell lines. mRNA values are expressed as Affymetrix MAS 5.0 intensity scaled to a trimmed mean of 500. GALNT14 IHC H-scores in cell lines with known sensitivity or resistance to (C) dulanermin \( (P = 0.01) \) and (D) drozitumab \( (P = 0.03) \); points, mean; bars, SD.
condensed into an H-score (20). Examples of samples with no staining and strong staining are illustrated in Fig. 3A and B, respectively. The frequency distribution of GALNT14 staining by H-score for all the samples is summarized in Fig. 3C. Using this scoring system, it is apparent that there is a broad range of staining in NSCLC, with 45% of samples having weak to moderate staining (arbitrarily defined as an H-score of >25).

**FUT3/6 IHC assay validation in CRC.** Mouse monoclonal antibodies to FUT6 were produced by immunizing mice with the FUT6 protein (amino acids 46-359), and then screening clones by ELISA and IHC on FFPE cell

---

Fig. 3. A wide spectrum of GALNT14 staining patterns is observed in NSCLC tissue ranging from no staining (A) to strongly positive (B). In all cases, dark-brown positive staining is noted in a punctate perinuclear pattern. C, GALNT14 staining in a panel of archival human NSCLC tumors. The frequency distribution is summarized by H-score. Scale bar, 50 μm

![Fig. 3](image)

Fig. 4. Examples of FUT3/6 IHC. Immunohistochemical staining patterns in cell lines and normal tissues known to express this enzyme (B and D) and known to lack this enzyme (A and C). Dark-brown positive staining is noted in a punctate perinuclear pattern consistent with the Golgi. A, HT29 CRC cell line; B, SW403 CRC cell line; C, normal prostate tissue; D, normal colon tissue. Scale bar, 50 μm.
pellets similar to the approach with GALNT14. It should be noted that FUT3 and FUT6 are highly homologous (84% identical and 90% similar based on amino acid sequence). Not surprisingly, most hybridomas cross-reacted with both antigens in an ELISA format. Whether the antibody chosen was specific for FUT6 over FUT3 was not considered to be critical because FUT3 and FUT6 expression are highly correlated (1), and both predict response to dulanermin equally well in CRC cell lines (1). The clone 1G11, which cross-reacts with FUT3 and FUT6 by ELISA, resulted in the expected punctate perinuclear IHC staining pattern characteristic of the Golgi apparatus in positive control cell pellets and was selected for further development on the Ventana BenchMark XT platform. An optimized IHC protocol was developed with a final primary antibody dilution of 1.3 μg/mL as described in Materials and Methods.

FUT3/6 IHC was examined in a panel of 32 CRC cell lines and was scored using the H-score (20). Some cell lines, such as HT29, exhibited no staining at all, and other cell lines, such as SW403, exhibited strong, punctate perinuclear staining (Fig. 4A and B). The IHC staining summarized by H-score was examined in relation to the mRNA expression of both FUT3 and FUT6 across the panel of cell lines. In both cases, IHC staining correlated with mRNA expression for FUT3 ($r^2 = 0.55$) and FUT6 ($r^2 = 0.45$; Fig. 5A and B). To address specificity, we turned to the three FUT family members most closely related at the protein level: FUT5 (85% identical, 88% similar), FUT7 (47% identical, 63% similar), and FUT4 (43% identical, 56% similar; ref. 23). Of these, only FUT4 is expressed in CRC (Supplementary Fig. S2A), the tumor type in which FUT3/6 is believed to predict response to dulanermin or drozitumab. Consequently, the correlation

![Fig. 5. FUT3/6 assay validation. Correlation of FUT3/6 IHC H-scores with (A) FUT3 mRNA levels ($r^2 = 0.55$) and (B) FUT6 mRNA levels ($r^2 = 0.45$) in 32 CRC cell lines, mRNA values expressed as Affymetrix MAS 5.0 intensity scaled to a trimmed mean of 500. FUT3/6 IHC H-scores in cell lines with known sensitivity or resistance to (C) dulanermin ($P = 0.0004$ for highly sensitive compared with resistant) and (D) drozitumab ($P < 0.0001$ for highly sensitive compared with resistant); points, mean; bars, SD.](https://www.aacrjournals.org/clin-cancer-research/article-pdf/16/5/1593/2685495/clin-cancer-research-16-5-1593.pdf)
between FUT3/6 IHC and FUT4 mRNA expression was examined in CRC cell lines. No evidence of correlation was found (Supplementary Fig. S2B), suggesting that the FUT3/6 IHC exhibits some level of specificity.

We next used the CRC cell lines to examine the correlation of FUT3/6 IHC H-scores with in vitro sensitivity to dulanermin and drozitumab. There was a very clear, statistically significant relationship between high FUT3/6 IHC staining and cell lines that were highly sensitive versus those that were resistant ($P = 0.0004$ for dulanermin and $P < 0.0001$ for drozitumab; Fig. 5C and D).

As a next step in evaluating specificity, FUT3 and FUT6 mRNA expression was examined in normal human tissues. Normal colon tissue was found to have relatively high expression for both, whereas normal prostate had relatively low expression for both (Supplementary Fig. S3). The FUT3/6 IHC staining was clearly positive in normal colonic epithelial cells, with the staining located on the luminal side of the nucleus consistent with the location of the Golgi; no staining was observed in normal prostate tissue (Fig. 4C and D), consistent with the known mRNA expression data.

Using the IHC protocol that was validated on cell lines and normal tissues, FUT3/6 was examined in a panel of 98 FFPE CRC tumors represented on two tissue microarrays. As with GALNT14, there was a range of FUT3/6 IHC staining from none (Fig. 6A) to uniform strong staining (Fig. 6B). All CRC samples were scored and summarized using H-scores (20). It is clear that there is a wide range of FUT3/6 staining intensity, with a relatively large percentage of CRC tumors (~70%) exhibiting moderate to strong staining (defined arbitrarily as H-score of >125, Fig. 6C).

**Discussion**

Recent studies have shown that the response to dulanermin and drozitumab in cell lines and xenograft models correlates with levels of the O-glycosylation enzymes GALNT14— in NSCLC, pancreatic cancer, malignant melanoma, and sarcoma—and FUT3/6 in CRC (1, 19). These findings in preclinical models suggest that these enzymes may be clinically useful biomarkers that predict which patients are more likely to derive benefit from dulanermin and drozitumab. Testing these findings in early-phase clinical trials involves the development of robust assays to measure levels of these enzymes in archival FFPE tumor samples. The current study shows that IHC can be used to assess GALNT14 and FUT3/6 in NSCLC and CRC tissue samples. The protocols developed for GALNT14 and FUT3/6 resulted in robust staining, with the punctate perinuclear pattern consistent with the localization in the Golgi. Based on a comparison with gene expression derived from a panel of cell lines and normal human tissues, there is evidence to suggest that these assays are specific for the targets in question.

In the present study, GALNT14 staining varied widely in human NSCLC tissue, with 45% of the samples having weak to moderate staining. FUT3/6 staining varied in CRC tissue, although a much larger proportion of samples having moderate to strong positive staining (70%). It should be noted that the scoring system used in the current study was chosen as a convenient way to summarize data, and is not meant to communicate potential cutoffs that might distinguish responders from nonresponders. Both markers will be examined in an exploratory manner in ongoing phase II trials of both dulanermin and drozitumab to determine whether there are simple cutoffs that distinguish responders from nonresponders.

Oncology diagnostics currently use a range of techniques to assess the molecular characteristics of tumor tissue, including IHC, fluorescent in situ hybridization, and quantitative real-time PCR. IHC methods have several advantages including the capability to measure biomarker expression in small numbers of tumor cells among a large normal cell population, being already...
established as a diagnostic technique that is widely used in hospital laboratories, and the ability to be performed in a rapid and cost-effective manner (24). IHC does have its challenges, however. It is generally considered to be qualitative rather than quantitative (25) and, when used for patient selection such as with human epidermal growth factor receptor 2, can under some conditions be subject to relatively high false-positive rates (refs. 26–30; resulting in treatment of patients who are unlikely to respond) as well as high false-negative rates (leading to exclusion of patients who may benefit from the treatment; ref. 29).

The development of testing accreditation guidelines for companion diagnostics, such as those developed by the American Society of Clinical Oncology and the College of American Pathologists for human epidermal growth factor receptor 2 testing in breast cancer (31), may help reduce discordant testing results not only for existing predictive diagnostic assays but also for those that may emerge in the future.

Differences in GALNT14 and FUT3/6 expression do not seem to be associated with alterations in gene copy number (1); consequently, fluorescent in situ hybridization is not appropriate for diagnostic identification of patients with overexpression of these enzymes. Quantitative real-time PCR may be an alternative method for measuring GALNT14 and FUT3/6, and may be more quantitative than IHC; however, it may be subject to potential dilution by normal cells, given the need to homogenize tissue rather than observe a signal specifically in tumor cells. Future experiments will address whether quantitative real-time PCR analysis of the O-glycosylation enzymes studied here, compared with IHC, has greater value in this clinical setting.

In conclusion, the IHC protocols developed in this study provide a robust, specific method of assessing the O-glycosylation enzymes, GALNT14 and FUT3/6, in archival FFPE human tissues. Both assays are currently being deployed in phase II clinical trials of dulanermin and drozitumab to further evaluate incorporating IHC analysis of specific O-glycosylation enzymes as a diagnostic component of future clinical development.

Disclosure of Potential Conflicts of Interest

H.M. Stern, L. Amler, and A. Ashkenazi: employees of Genentech, shareholders of Roche; K. Wagner: consultant, Genentech; M. Padilla: employee, Ventana Medical Systems, Inc.

Acknowledgments

We thank Patti Tobin, Ling Huw, Terrence Wong, Theresa Shek, and the Department of Protein Chemistry at Genentech for technical assistance.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 11/24/2009; accepted 12/29/2009; published OnlineFirst 02/23/2010.

References

23. Oriol R, Mollicone R, Cailleur B, Balanzino L, Breton C. Divergent


Clinical Cancer Research

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab

Howard M. Stern, Mary Padilla, Klaus Wagner, et al.

Clin Cancer Res 2010;16:1587-1596. Published OnlineFirst February 23, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-3108

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2010/03/01/1078-0432.CCR-09-3108.DC1

Cited articles
This article cites 31 articles, 11 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/16/5/1587.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
/content/16/5/1587.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.